Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Next Previous
Search
Trial Profile

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Margetuximab (Primary) ; Capecitabine; Eribulin; Gemcitabine; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SOPHIA
  • Sponsors MacroGenics

Most Recent Events

  • 04 Nov 2022 Results assessing safety and efficacy of margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer, published in the Journal of Clinical Oncology.
  • 28 Oct 2022 Status changed from active, no longer recruiting to completed.
  • 18 Sep 2022 This trial has been completed in Denmark (Date of the global end of the trial : 14-Jun-2022), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top